OncoMatch/Clinical Trials/NCT05620290
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer
Is NCT05620290 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Definity and Sonalleve Focused Ultrasound Device for melanoma.
Treatment: Definity · Sonalleve Focused Ultrasound Device — The objective of this study is to examine the safety profile and therapeutic efficacy of MRI-guided focused ultrasound microbubble therapy and radiotherapy in humans.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunotherapy
Patient on immunotherapy.
Lab requirements
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above the institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded]
Cardiac function
No severe cardiovascular disease, unstable hemodynamics, myocardial infarction within six months, unstable angina, congestive heart failure, ejection fraction < 50%, cardiac shunts, cardiac arrhythmia, cardiac pacemaker, or severe hypertension (diastolic BP > 100 mmHg)
Severe cardiovascular, neurological, renal or hematological chronic disease. Cardiac disease or unstable hemodynamics, including myocardial infarction within six months, unstable angina, congestive heart failure, ejection fraction < 50%, cardiac shunts, cardiac arrhythmia and cardiac pacemaker. Severe hypertension (diastolic BP > 100 mmHg). Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05620290 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immunotherapy.
What disease stage is eligible?
Stage I or II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages